Roche Holding AG : Back on key levels based on weekly price data
Entry price | Target | Stop-loss | Potential |
---|
CHF 309.4 |
CHF 333 |
CHF 300 |
+7.63% |
---|
Roche Holding AG shares have returned to important technical levels around 303.35 CHF based on weekly price data. The timing seems attractive to be a buyer of this stock.
Summary● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● The company is in a robust financial situation considering its net cash and margin position.
● Analyst opinion has improved significantly over the past four months.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● The company's enterprise value to sales, at 4.07 times its current sales, is high.
● The company appears highly valued given the size of its balance sheet.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.